Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H21NS.ClH |
Molecular Weight | 331.903 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN(C)CC\C=C1/C2=C(CSC3=C1C=CC=C3)C=CC=C2
InChI
InChIKey=XUPZAARQDNSRJB-SJDTYFKWSA-N
InChI=1S/C19H21NS.ClH/c1-20(2)13-7-11-17-16-9-4-3-8-15(16)14-21-19-12-6-5-10-18(17)19;/h3-6,8-12H,7,13-14H2,1-2H3;1H/b17-11+;
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C19H21NS |
Molecular Weight | 295.442 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/2670509Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/8447840 | https://www.drugs.com/uk/dosulepin-capsules-25mg-leaflet.html | https://www.ncbi.nlm.nih.gov/pubmed/9408183
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2670509
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/8447840 | https://www.drugs.com/uk/dosulepin-capsules-25mg-leaflet.html | https://www.ncbi.nlm.nih.gov/pubmed/9408183
cis-Dosulepin is a stereoisomer of Dothiepin (trade name Prothiaden, Dothep, Thaden, and Dopress; Dosulepin (INN, BAN) a tricyclic antidepressant that is used in several European and South Asian countries, as well as Australia, South Africa, and New Zealand. Dosulepin is used for the treatment of the major depressive disorder and neuropathic pain. Dosulepin is only Therapeutic Goods Administration and Medicines and Healthcare products Regulatory Agency approved for the treatment of the major depressive disorder. Dothiepin is not used in the United States. The central action of cis-dosulepin was compared with that of its antidepressant stereoisomer trans-dosulepin, cis-dosulepin exerted weaker anti-reserpine, anti-tetrabenazine, and 3H-5-HT (serotonin) uptake inhibiting actions than trans-dosulepin, but cis-dosulepin's inhibition of 3H-dopamine and 3H-norepinephrine uptake was slightly more potent than that of trans-dosulepin. On the other hand, cis-dosulepin exhibited extremely potent anticholinergic action in oxotremorine induced tremor, isolated ileum and the 3H-quinuclidinyl benzilate binding test. It also showed potent apomorphine enhancing the action and shortened the period of immobility in the forced swimming test in animals.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P35367 Gene ID: 3269.0 Gene Symbol: HRH1 Target Organism: Homo sapiens (Human) |
8.4 null [pKi] | ||
18.0 nM [Kd] | |||
109.0 nM [Kd] | |||
38.0 nM [Kd] | |||
61.0 nM [Kd] | |||
92.0 nM [Kd] | |||
Target ID: CHEMBL228 Sources: https://www.drugbank.ca/drugs/DB09167 |
8.6 nM [Kd] | ||
Target ID: CHEMBL222 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9537821 |
46.0 nM [Kd] | ||
Target ID: CHEMBL228 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8447840 |
|||
Target ID: CHEMBL238 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8447840 |
|||
Target ID: CHEMBL222 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8447840 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Prothiaden Approved UseUnknown |
|||
Primary | Prothiaden Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
A comparative study of the therapeutic effect and cardiotoxicity of dothiepin HCl and doxepin HCl in reactive depression. | 1981 |
|
Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics. | 1993 Jun 9 |
|
Exacerbation of extrapyramidal symptoms with paroxetine. | 1995 Sep |
|
Nightmares and hallucinations after long-term intake of tramadol combined with antidepressants. | 1996 |
|
Pharmacological profile of antidepressants and related compounds at human monoamine transporters. | 1997 Dec 11 |
|
Antidepressant drugs and heart electrical field. | 1998 |
|
Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding. | 1999 Aug |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9408183
male Slc:Wistar rats: 40 mg/kg, PO
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:10:28 GMT 2023
by
admin
on
Fri Dec 15 15:10:28 GMT 2023
|
Record UNII |
3H0042311V
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C265
Created by
admin on Fri Dec 15 15:10:28 GMT 2023 , Edited by admin on Fri Dec 15 15:10:28 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID7047778
Created by
admin on Fri Dec 15 15:10:28 GMT 2023 , Edited by admin on Fri Dec 15 15:10:28 GMT 2023
|
PRIMARY | |||
|
142133
Created by
admin on Fri Dec 15 15:10:28 GMT 2023 , Edited by admin on Fri Dec 15 15:10:28 GMT 2023
|
PRIMARY | RxNorm | ||
|
SUB01821MIG
Created by
admin on Fri Dec 15 15:10:28 GMT 2023 , Edited by admin on Fri Dec 15 15:10:28 GMT 2023
|
PRIMARY | |||
|
CHEMBL1492500
Created by
admin on Fri Dec 15 15:10:28 GMT 2023 , Edited by admin on Fri Dec 15 15:10:28 GMT 2023
|
PRIMARY | |||
|
3H0042311V
Created by
admin on Fri Dec 15 15:10:28 GMT 2023 , Edited by admin on Fri Dec 15 15:10:28 GMT 2023
|
PRIMARY | |||
|
C78018
Created by
admin on Fri Dec 15 15:10:28 GMT 2023 , Edited by admin on Fri Dec 15 15:10:28 GMT 2023
|
PRIMARY | |||
|
212-978-8
Created by
admin on Fri Dec 15 15:10:28 GMT 2023 , Edited by admin on Fri Dec 15 15:10:28 GMT 2023
|
PRIMARY | |||
|
DBSALT001822
Created by
admin on Fri Dec 15 15:10:28 GMT 2023 , Edited by admin on Fri Dec 15 15:10:28 GMT 2023
|
PRIMARY | |||
|
100000091934
Created by
admin on Fri Dec 15 15:10:28 GMT 2023 , Edited by admin on Fri Dec 15 15:10:28 GMT 2023
|
PRIMARY | |||
|
6433931
Created by
admin on Fri Dec 15 15:10:28 GMT 2023 , Edited by admin on Fri Dec 15 15:10:28 GMT 2023
|
PRIMARY | |||
|
m4748
Created by
admin on Fri Dec 15 15:10:28 GMT 2023 , Edited by admin on Fri Dec 15 15:10:28 GMT 2023
|
PRIMARY | Merck Index | ||
|
31519
Created by
admin on Fri Dec 15 15:10:28 GMT 2023 , Edited by admin on Fri Dec 15 15:10:28 GMT 2023
|
PRIMARY | |||
|
172130
Created by
admin on Fri Dec 15 15:10:28 GMT 2023 , Edited by admin on Fri Dec 15 15:10:28 GMT 2023
|
PRIMARY | |||
|
897-15-4
Created by
admin on Fri Dec 15 15:10:28 GMT 2023 , Edited by admin on Fri Dec 15 15:10:28 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |